JRCT ID: jRCT2080223920
Registered date:01/06/2018
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 12/07/2018 |
Target sample size | 780 |
Countries of recruitment | Japan,North America,Europe |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Pembrolizumab, Lenvatinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Paclitaxel, Doxorubicin Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy efficacy |
---|---|
Secondary Outcome | efficacy efficacy safety pharmacokinetics safety efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Female |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03517449,JapicCTI-183977 |
Contact
Public contact | |
Name | |
Address | |
Telephone | - |
JPCT@merck.com | |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | - |
JPCT@merck.com | |
Affiliation |